Rosenblatt has reiterated a Buy rating on IMAX Corporation (NYSE:IMAX) and maintained a $47.00 price target as the company prepares to report quarterly results Wednesday evening. The firm’s note characterizes IMAX as a global, end-to-end entertainment platform that leverages Hollywood releases, local-language productions and alternative content to drive incremental revenue and margin expansion within a business that carries substantial fixed costs.
In its outlook, Rosenblatt points to the 2026 film slate as a material factor that could sustain the outperformance versus expectations that helped lift the stock in 2025. The research house argues that IMAX is frequently misunderstood as primarily a play on a weak domestic box office, and instead frames the company as one that can expand margins by driving higher ticket sales and content differentiation across markets.
Rosenblatt’s $47 price objective is derived from a 13 times enterprise value to calendar-year 2026 EBITDA multiple. The firm notes that this multiple sits below the mid-teens multiple at which the shares have historically traded, implying potential for multiple expansion if the company executes on its strategy. The note also references a current valuation of 10 times enterprise value to 2026 EBITDA, which Rosenblatt views as providing additional room for upside should operating results and market sentiment improve.
Supporting the valuation view, InvestingPro analysis cited by Rosenblatt highlights that IMAX is trading at a low price-to-earnings ratio relative to near-term earnings growth and that net income is expected to increase this year. The stock has already recorded a notable price uptick over the past six months, and InvestingPro is tracking 11 additional tips for subscribers tied to the name.
Separately, Benchmark reported that IMAX’s fourth-quarter 2025 performance exceeded expectations and pointed to solid box office momentum that appears to be carrying into the first quarter of 2026. Benchmark noted that January box office receipts were approximately $65 million, approaching January of last year when total receipts reached $69 million for the month. Benchmark has retained its Buy rating on IMAX, with a $42.00 price target and a constructive view on the company’s prospects into 2026.
Together, the Rosenblatt and Benchmark notes present a consistent picture of analysts emphasizing both near-term box office momentum and a valuation framework that could support upside if IMAX’s execution and the film slate meet expectations. The company’s upcoming earnings release will provide investors with fresh data to assess those dynamics.
Summary
Rosenblatt reaffirmed a Buy rating and $47.00 target on IMAX ahead of earnings, using a 13x EV to 2026 EBITDA multiple as the basis. The firm highlighted the potential of IMAX’s 2026 film slate and pointed to a current valuation of 10x EV to 2026 EBITDA as room for multiple expansion. Benchmark also reported better-than-expected Q4 2025 results and positive early-2026 box office trends, maintaining its Buy rating with a $42.00 target.